Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2026-02-17 00:00:00 ET · period of report 2026-02-12 · accession 0001701247-26-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-17 | 2026-02-12 | ELVN | Collins Helen Louise | Chief MEDICAL Off | A - Grant | $0.00 | +25.0K | 25.0K | New | $0 |
| D | 2026-02-17 | 2026-02-12 | ELVN | Collins Helen Louise | Chief MEDICAL Off | A - Grant | $0.00 | +150.0K | 150.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-12 | A | A | 25,000 | $0.00 | 25,000 | D | — | — | (F1) These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
| 2 | Derivative | Stock Option (right to buy) | 2026-02-12 | A | A | 150,000 | $0.00 | 150,000 | D | $27.16 · — to 2036-02-12 | 150,000 Common Stock | (F2) 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |